Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, Srdan Verstovsek

Research output: Contribution to journalReview articlepeer-review

226 Scopus citations

Abstract

Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia and myelofibrosis have led to the identification of the mutation V617F in Janus kinase (JAK) as a potential therapeutic target. This information has prompted the development of ATP-competitive JAK2 inhibitors. Therapy with JAK2 inhibitors may induce rapid and marked reductions in spleen size and can lead to remarkable improvements in constitutional symptoms and overall quality of life. Because JAKs are involved in the pathogenesis of inflammatory and immune-mediated disorders, JAK inhibitors are also being tested in clinical trials in patients with rheumatoid arthritis and psoriasis, as well as for the treatment of other autoimmune diseases and for the prevention of allograft rejection. Preliminary results indicate that these agents hold great promise for the treatment of JAK-driven disorders.

Original languageEnglish (US)
Pages (from-to)127-140
Number of pages14
JournalNature Reviews Drug Discovery
Volume10
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond'. Together they form a unique fingerprint.

Cite this